Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors.

Clin Pharmacol Drug Dev · 2022 · PMC9306994 · PMID 35187855

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

The RSE on this estimate was 42% and the corresponding 90%CI was −0.0273 to −0.000759, indicating only a marginally significant effect.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.